English Abstract
Journal Article
Review
Add like
Add dislike
Add to saved papers

[HTLV-I virus and associated chronic neuromyelopathies. Current data and hypotheses].

Human T cell leukemia/lymphoma virus type I (HTLV-I) isolated in 1980, is a human retrovirus. This CD4+ lymphotropic type C retrovirus is endemic in South Western Japan, the Caribbean region and Africa where it is associated with a rare form of lymphoproliferative disease, adult T cell leukemia. Recently, HTLV-I antibodies has been found in sera and CSF from patients with tropical spastic paraparesis (TSP), a chronic neuromyelopathy of unknown etiology common in tropical areas and in Japanese patients with a similar clinical myelopathy. These data suggest that HTLV-I or an antigenically related virus might be neurotropic or neurovirulent and etiologically linked to such chronic neuromyelopathies. The fact that TSP affects about 10 to 100 persons/100,000 in tropical HTLV-I endemic areas, a prevalence comparable to that of multiple sclerosis in temperate regions, increases considerably the public health interest in HTLV-I and associated diseases. The possible neurotropism or neurovirulence of this retrovirus is discussed.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app